Bleeding: Numbers of patients with at least one significant bleeding event · People with a haematological disorder
Prophylactic platelet transfusion at threshold of 10,000 showed no clear difference in bleeding: Numbers of patients with at least one significant bleeding… compared with higher transfusion threshold (20,000 or 30,000) (moderate certainty).
1 finding from 1 review
Mortality: secondary to bleeding · People with a haematological disorder
Prophylactic platelet transfusion at threshold of 10,000 showed no clear difference in mortality: secondary to bleeding compared with higher transfusion threshold (20,000 or 30,000) (low certainty).
1 finding from 1 review
Number of participants with WHO grade 3 or 4 bleeding up to 30 days from study entry · People with a haematological disorder
Prophylactic platelet transfusions with low‐dose schedule showed no clear difference in number of participants with WHO grade 3 or 4 bleeding up to 30 days… compared with high‐dose schedule (low certainty).
1 finding from 1 review
Time to first bleeding episode (days) · People with a haematological disorder
1 finding from 1 review
Mortality from all causes up to 30 days from study entry · People with a haematological disorder
Prophylactic platelet transfusions with low‐dose schedule showed no clear difference in mortality from all causes up to 30 days from study entry compared with high‐dose schedule (low certainty).
1 finding from 1 review
Number of platelet transfusions per participant up to 30 days from study entry · People with a haematological disorder
1 finding from 1 review
Quality of life ‐ not reported · People with a haematological disorder
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found
Number of participants with at least 1 clinically significant bleeding event up to 30 days from study entry · People with a haematological disorder
Prophylactic platelet transfusions with low‐dose schedule showed no clear difference in number of participants with at least 1 clinically significant… compared with high‐dose schedule (moderate certainty).
1 finding from 1 review
Number of days on which bleeding occurred per participant up to 30 days from study entry · People with a haematological disorder
1 finding from 1 review
Number of participants with at least 1 clinically significant bleeding event up to 30 days from study entry · People with a haematological disorder
Prophylactic platelet transfusions with high‐dose schedule showed no clear difference in number of participants with at least 1 clinically significant… compared with standard‐dose schedule (moderate certainty).
1 finding from 1 review
Number of days on which bleeding occurred per participant up to 30 days from study entry · People with a haematological disorder
1 finding from 1 review
Number of participants with WHO grade 3 or 4 bleeding up to 30 days from study entry · People with a haematological disorder
Prophylactic platelet transfusions with high‐dose schedule showed no clear difference in number of participants with WHO grade 3 or 4 bleeding up to 30 days… compared with standard‐dose schedule (low certainty).
1 finding from 1 review
Time to first bleeding episode (days) · People with a haematological disorder
1 finding from 1 review
Number of platelet transfusions per participant up to 30 days from study entry · People with a haematological disorder
1 finding from 1 review
Mortality from all causes up to 30 days from study entry · People with a haematological disorder
Prophylactic platelet transfusions with high‐dose schedule showed no clear difference in mortality from all causes up to 30 days from study entry compared with standard‐dose schedule (low certainty).
1 finding from 1 review
Quality of life ‐ not reported · People with a haematological disorder
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found
Number of transfusions per participant within 7 days ‐ not reported · patients undergoing non‐cardiac surgery/invasive procedures
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found
Blood transfusion · patients undergoing non‐cardiac surgery/invasive procedures
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found
Serious adverse events measured by plasma transfusion‐related complications within 24 hours № of participants: 21 (1 RCT) · patients undergoing non‐cardiac surgery/invasive procedures
It is very uncertain whether prophylactic plasma transfusion before surgery/invasive procedures changes serious adverse events measured by plasma transfusion‐related… compared with alternative haemostatic agents (very low certainty).
1 finding from 1 review
RR 9.82 [0.59, 162.24]
Studies not reported
Very low
Serious adverse events measured by surgery or procedure‐related complications within 30 days ‐ not reported · patients undergoing non‐cardiac surgery/invasive procedures
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found